Log in
Enquire now
‌

US Patent 10167471 Inhibition of PCSK9 through RNAI

Patent 10167471 was granted and assigned to Rxi Pharmaceuticals Corporation on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
‌
Rxi Pharmaceuticals Corporation
0
Date Filed
October 6, 2016
0
Date of Patent
January 1, 2019
0
Patent Applicant
‌
Rxi Pharmaceuticals Corporation
0
Patent Application Number
15286948
0
Patent Citations Received
‌
US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
0
‌
US Patent 11021707 Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
‌
US Patent 11254940 Inhibition of MAP4K4 through RNAi
‌
US Patent 11279934 Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
‌
US Patent 11667915 RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
0
‌
US Patent 11396654 Neutral nanotransporters
‌
US Patent 10479992 RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
‌
US Patent 10633654 Modified RNAi polynucleotides and uses thereof
‌
US Patent 10662430 RNA interference in ocular indications
‌
US Patent 10774330 Reduced size self-delivering RNAI compounds
•••
Patent Inventor Names
Anastasia Khvorova
0
Joanne Kamens
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10167471
0
Patent Primary Examiner
‌
Amy H Bowman
0

Find more entities like US Patent 10167471 Inhibition of PCSK9 through RNAI

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.